Specialized Medications Arrive for Cancer Treatment
The National Cancer Control Authority announced the arrival of a new shipment from Johnson Company containing specialized medicines for cancer treatment. The goal is to enhance the availability of medications and support the continuity of treatment protocols for cancer patients. The shipment includes Darzalex at a concentration of 400 mg and Orserdu at a concentration of 345 mg. The Authority affirms its ongoing efforts to monitor the needs of medical centers and institutions to ensure the delivery of medications to those in need, thereby contributing to improved quality of treatment and meeting the therapeutic needs of cancer patients.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)